While there are no FDA-approved MDM2 inhibitors on the market yet, one (KT-253) has received an FDA orphan drug designation for AML and a few others are being evaluated in Phase III studies for the treatment of TP53 wild-type cancer [85]. Here, TP53 is linked to cancer.